BR112015009070A2 - proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas - Google Patents

proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas

Info

Publication number
BR112015009070A2
BR112015009070A2 BR112015009070A BR112015009070A BR112015009070A2 BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2 BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2
Authority
BR
Brazil
Prior art keywords
fusion protein
cocktail
mycobacterium
antigens
virulent
Prior art date
Application number
BR112015009070A
Other languages
English (en)
Portuguese (pt)
Inventor
Aagaard Claus
Rosenkrands Ida
Andersen Peter
Thi Kim Thanh Hoang Truc
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BR112015009070A2 publication Critical patent/BR112015009070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015009070A 2012-10-23 2013-10-18 proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas BR112015009070A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201200652 2012-10-23
DKPA201200654 2012-10-23
DKPA201200653 2012-10-23
DKPA201300477 2013-08-23
PCT/DK2013/000070 WO2014063704A2 (en) 2012-10-23 2013-10-18 M. tuberculosis vaccines

Publications (1)

Publication Number Publication Date
BR112015009070A2 true BR112015009070A2 (pt) 2017-07-04

Family

ID=49679267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009070A BR112015009070A2 (pt) 2012-10-23 2013-10-18 proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas

Country Status (8)

Country Link
US (1) US9526773B2 (https=)
EP (1) EP2912056B1 (https=)
JP (1) JP6470179B2 (https=)
CN (1) CN104736555B (https=)
BR (1) BR112015009070A2 (https=)
IN (1) IN2015DN03962A (https=)
WO (1) WO2014063704A2 (https=)
ZA (1) ZA201503467B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104380A1 (en) * 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
JP2018527395A (ja) * 2015-09-30 2018-09-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 改良モジュール型抗原移送分子及び動物におけるその使用
CN105218681B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生结核特异性细胞因子的融合蛋白
CN105218680B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CN109843321A (zh) 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 作为结核病疫苗的重组巨细胞病毒载体
US10684275B2 (en) 2016-12-14 2020-06-16 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
KR102589422B1 (ko) * 2017-01-09 2023-10-13 바이오뮤넥스 파마슈티컬스 다중특이적 항체를 제조하기 위한 폴리펩티드 링커
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
EP3983011A1 (en) 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
US12599655B2 (en) 2019-08-01 2026-04-14 Trustees Of Tufts College Neisseria gonorrhoeae vaccine compositions and methods of selecting antigens
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN118765203A (zh) 2022-02-21 2024-10-11 史坦恩斯血清研究所 一种新型阳离子佐剂组合物
CN115300618B (zh) * 2022-05-11 2026-03-27 中国农业大学 基于牛β防御素5的结核疫苗及其在预防结核病中的应用
CN115184603B (zh) * 2022-06-30 2024-02-06 首都医科大学附属北京胸科医院 EspC蛋白在制备结核分枝杆菌分离或富集产品中的应用
KR20250087737A (ko) * 2023-12-06 2025-06-17 주식회사 미코라파 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用
US20250387462A1 (en) * 2024-06-21 2025-12-25 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infections
CN119823286B (zh) * 2025-01-16 2026-02-06 中国动物卫生与流行病学中心 一种重组蛋白抗原及其在制备用于检测牛伽马干扰素试剂盒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
ATE535600T1 (de) * 2002-04-05 2011-12-15 Pasteur Institut Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht
MX2011011186A (es) * 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Also Published As

Publication number Publication date
CN104736555A (zh) 2015-06-24
EP2912056B1 (en) 2020-02-12
ZA201503467B (en) 2016-11-30
CN104736555B (zh) 2019-06-21
US9526773B2 (en) 2016-12-27
WO2014063704A3 (en) 2014-06-19
JP2015536309A (ja) 2015-12-21
IN2015DN03962A (https=) 2015-10-02
US20150290311A1 (en) 2015-10-15
JP6470179B2 (ja) 2019-02-13
EP2912056A2 (en) 2015-09-02
WO2014063704A2 (en) 2014-05-01
WO2014063704A8 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
MX2022002106A (es) Formulaciones de vacuna de vial unico.
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MY173004A (en) Mycobacterial antigen vaccine
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
EA201790239A1 (ru) Молекула-носитель для антигенов
WO2006136162A3 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
EA201892568A1 (ru) Способы получения контрастных средств для ультразвукового исследования
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
MX2018013172A (es) Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
BR112016016103A2 (pt) Composição de antígenos micobacterianos
MX380411B (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
MX2016013277A (es) Vacuna para estreptococo de grupo a.
WO2015144732A3 (en) Uses of parasite macrophage migration inhibitory factors
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
MX388527B (es) Composiciones adyuvantes y metodos relacionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.